Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John-Patrick Mpindi

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Bioinformatics (Oxford, England)|August 9, 2015
Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response dataJohn-Patrick Mpindi, Potdar Swapnil, Bychkov Dmitrii, et al.
Plos One|July 5, 2012
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerPaula Vainio, John-Patrick Mpindi, Pekka Kohonen, et al.
Cancer Research|August 18, 2010
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cellsSantosh Gupta, Kristiina Iljin, Henri Sara, et al.
Plos One|May 11, 2010
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responsesVille Härmä, Johannes Virtanen, Rami Mäkelä, et al.
BMC Bioinformatics|June 1, 2012
Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugsSuleiman A Khan, Ali Faisal, John Patrick Mpindi, et al.
Bioinformatics (Oxford, England)|March 3, 2020
Breeze: an integrated quality control and data analysis application for high-throughput drug screeningSwapnil Potdar, Aleksandr Ianevski, John-Patrick Mpindi, et al.
The Prostate|September 16, 2011
Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancerPaula Vainio, Maija Wolf, Henrik Edgren, et al.
European Urology|October 23, 2015
Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor TissueAnna Aakula, Pekka Kohonen, Suvi-Katri Leivonen, et al.
Plos One|October 27, 2011
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cellsSanna Siltanen, Tiina Wahlfors, Martin Schindler, et al.
The American Journal of Pathology|February 2, 2011
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerPaula Vainio, Santosh Gupta, Kirsi Ketola, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Bioinformatics (Oxford, England)|August 9, 2015
Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose-response dataJohn-Patrick Mpindi, Potdar Swapnil, Bychkov Dmitrii, et al.
Plos One|July 5, 2012
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerPaula Vainio, John-Patrick Mpindi, Pekka Kohonen, et al.
Cancer Research|August 18, 2010
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cellsSantosh Gupta, Kristiina Iljin, Henri Sara, et al.
Plos One|May 11, 2010
A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responsesVille Härmä, Johannes Virtanen, Rami Mäkelä, et al.
BMC Bioinformatics|June 1, 2012
Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugsSuleiman A Khan, Ali Faisal, John Patrick Mpindi, et al.
Bioinformatics (Oxford, England)|March 3, 2020
Breeze: an integrated quality control and data analysis application for high-throughput drug screeningSwapnil Potdar, Aleksandr Ianevski, John-Patrick Mpindi, et al.
The Prostate|September 16, 2011
Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancerPaula Vainio, Maija Wolf, Henrik Edgren, et al.
European Urology|October 23, 2015
Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor TissueAnna Aakula, Pekka Kohonen, Suvi-Katri Leivonen, et al.
Plos One|October 27, 2011
Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cellsSanna Siltanen, Tiina Wahlfors, Martin Schindler, et al.
The American Journal of Pathology|February 2, 2011
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerPaula Vainio, Santosh Gupta, Kirsi Ketola, et al.
Pageof 3